HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

G K Wenning Selected Research

G K Wenning Research Topics

Disease

17	Parkinsonian Disorders (Parkinsonism) 10/2010 - 01/2000
14	Multiple System Atrophy 06/2011 - 01/2000
12	Parkinson Disease (Parkinson's Disease) 01/2016 - 03/2000
12	Striatonigral Degeneration 08/2005 - 01/2000
7	Dementia (Dementias) 10/2010 - 04/2000
6	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2016 - 01/2000
4	Cerebellar Ataxia (Dysmetria) 10/2010 - 06/2001
4	Dystonia (Limb Dystonia) 05/2004 - 03/2002
4	Dyskinesias (Dyskinesia) 04/2004 - 09/2000
3	Disease Progression 10/2010 - 01/2001
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 06/2011 - 08/2005
2	Orthostatic Hypotension (Postural Hypotension) 01/2007 - 12/2005
2	Astrocytoma (Pilocytic Astrocytoma) 04/2002 - 09/2001
2	Atrophy 01/2001 - 05/2000
1	Frontotemporal Lobar Degeneration (Semantic Dementia) 06/2011
1	Sarcoma (Soft Tissue Sarcoma) 06/2011
1	Movement Disorders (Movement Disorder) 10/2010
1	Myoclonus (Nocturnal Myoclonus) 10/2010
1	Apraxias (Dyspraxia) 10/2010
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 10/2010
1	Paralysis (Palsy) 10/2010
1	Pain (Aches) 05/2004
1	Blepharospasm 07/2002
1	Torticollis (Wryneck) 07/2002
1	Dystonic Disorders (Writer's Cramp) 03/2002
1	Huntington Disease (Huntington's Disease) 10/2001
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 12/2000
1	REM Sleep Behavior Disorder 12/2000
1	Hallucinations (Hallucination) 12/2000
1	Syncope (Fainting) 12/2000
1	Brain Injuries (Brain Injury) 09/2000
1	Gliosis 07/2000
1	Confusion (Bewilderment) 04/2000

Drug/Important Bio-Agent (IBA)

15	Levodopa (L Dopa)FDA LinkGeneric 10/2010 - 01/2000
4	Riluzole FDA LinkGeneric 10/2006 - 01/2001
3	pamidronate (APD)FDA LinkGeneric 01/2016 - 03/2002
3	Botulinum Toxins (Botulinum Toxin)IBA 05/2004 - 03/2002
3	3-nitropropionic acidIBA 12/2002 - 05/2000
3	alpha-SynucleinIBA 04/2002 - 01/2000
3	Quinolinic AcidIBA 01/2001 - 01/2000
2	hydroxide ionIBA 01/2007 - 12/2005
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2002 - 05/2000
2	Oxidopamine (6 Hydroxydopamine)IBA 01/2001 - 01/2000
2	Dopamine (Intropin)FDA LinkGeneric 01/2001 - 01/2000
2	ApomorphineIBA 09/2000 - 01/2000
1	tebufenozide (Mimic)IBA 01/2016
1	protein TDP-43 (TDP-43)IBA 06/2011
1	DNA-Binding Proteins (DNA Binding Protein)IBA 06/2011
1	DNA (Deoxyribonucleic Acid)IBA 12/2005
1	Biological Markers (Surrogate Marker)IBA 12/2005
1	Protons (Proton)IBA 12/2005
1	Neuroprotective AgentsIBA 01/2004
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 10/2001
1	SynucleinsIBA 09/2001
1	red fluorescent proteinIBA 09/2001
1	Glutamic Acid (Glutamate)FDA Link 01/2001
1	Acetylcholine (Acetylcholine Chloride)FDA Link 12/2000
1	Antipsychotic Agents (Antipsychotics)IBA 12/2000
1	N-Methylaspartate (NMDA)IBA 09/2000
1	3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamideIBA 09/2000
1	Amantadine (Aman)FDA LinkGeneric 09/2000
1	PK 11195 (PK11195)IBA 07/2000
1	BenzodiazepinesIBA 07/2000
1	spiroperidol receptorIBA 01/2000
1	SCH 23390IBA 01/2000
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2000
1	Carbon MonoxideIBA 01/2000
1	Mazindol (Mazanor)FDA Link 01/2000

Therapy/Procedure

5	Transplants (Transplant) 01/2001 - 01/2000
3	Transplantation (Transplant Recipients) 01/2001 - 01/2000
2	Activities of Daily Living (ADL) 10/2006 - 05/2004
1	Denervation 12/2002
1	Drug Therapy (Chemotherapy) 03/2002
1	Injections 03/2002
1	Homologous Transplantation (Allograft) 01/2001
1	Aftercare (After-Treatment) 09/2000